XML 37 R26.htm IDEA: XBRL DOCUMENT
v3.19.1

Organization and Significant Accounting Policies - Additional Information (Detail) |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 28, 2016 USD ($) | Oct. 31, 2018 USD ($) Target $ / shares shares | Mar. 31, 2019 USD ($) shares | Mar. 31, 2018 USD ($) shares | Mar. 31, 2019 USD ($) shares | Mar. 31, 2018 USD ($) shares | Apr. 30, 2019 USD ($) | Sep. 30, 2018 USD ($) | Aug. 01, 2018 USD ($) | Sep. 30, 2017 USD ($)
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Proceeds from the issuance of common stock |  |  |  |  | $ 60,521,729 | $ 56,585,035 |  |  |  |
Cash and cash equivalents |  |  | $ 161,639,208 | $ 69,805,117 | 161,639,208 | $ 69,805,117 |  | $ 30,133,213 |  | $ 24,838,567
Short term investments |  |  | 56,560,674 |  | 56,560,674 |  |  | 46,400,176 |  |
Long term investments |  |  | 67,536,054 |  | 67,536,054 |  |  |  |  |
Net increase (decrease) in cash and investments |  |  |  |  | 209,200,000 |  |  |  |  |
Restricted Cash |  |  | 0 |  | 0 |  |  | 0 |  |
Fair value of contingent consideration obligation due to discontinuation of clinical trials |  |  | $ 0 |  | $ 0 |  |  | $ 0 |  |
Calculation of effect of dilutive stock options and restricted stock units | shares |  |  | 3,927,237 | 0 | 4,590,931 | 0 |  |  |  |
Stock Options |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Anti-dilutive excluded for calculation of effect of dilutive stock options and restricted stock units | shares |  |  | 917,175 |  | 989,175 |  |  |  |  |
Restricted Stock Units |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Anti-dilutive excluded for calculation of effect of dilutive stock options and restricted stock units | shares |  |  | 2,000 |  | 2,000 |  |  |  |  |
Collaboration and License agreements | Amgen |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Cash received as due under collaboration agreement | $ 35,000,000 |  |  |  |  |  |  |  |  |
Proceeds from the issuance of common stock | 21,500,000 |  |  |  |  |  |  |  |  |
AMG-890 (ARO-LPA) Agreement | Amgen |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  | $ 10,000,000 |
Janssen and JJDC | Collaboration and License agreements |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Cash received as due under collaboration agreement |  | $ 175,000,000 |  |  | $ 175,000,000 |  |  |  |  |
Proceeds from the issuance of common stock |  | $ 75,000,000 |  |  | $ 75,000,000 |  |  |  |  |
Janssen | Collaboration Agreement |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Number of additional targets for development and sales milestone payments | Target |  | 3 |  |  |  |  |  |  |  |
Janssen | JNJ-3989 (ARO-HBV) Agreement | Subsequent Event |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  | $ 25,000,000 |  |  |
Common Stock Purchase Agreement | JJDC |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Shares issued | shares |  | 3,260,869 |  |  |  |  |  |  |  |
Stock issued, price per share | $ / shares |  | $ 23.00 |  |  |  |  |  |  |  |
Common Stock Purchase Agreement | Janssen and JJDC |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Shares issued | shares |  | 3,260,869 |  |  |  |  |  |  |  |
Stock issued, price per share | $ / shares |  | $ 23.00 |  |  |  |  |  |  |  |
Proceeds from the issuance of common stock |  | $ 75,000,000 |  |  |  |  |  |  |  |
Minimum |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Property and equipment, useful life |  |  |  |  | 3 years |  |  |  |  |
Maximum |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Amount insured in FDIC per account |  |  | $ 250,000 |  | $ 250,000 |  |  |  |  |
Property and equipment, useful life |  |  |  |  | 7 years |  |  |  |  |
Maximum | Collaboration and License agreements | Amgen |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Option payments, and development, regulatory and sales milestone payments. | $ 617,000,000 |  |  |  |  |  |  |  |  |
Maximum | Janssen | License Agreement |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Development regulatory and sales milestones payments |  | 1,600,000,000 |  |  |  |  |  |  |  |
Maximum | Janssen | Collaboration Agreement |  |  |  |  |  |  |  |  |  |
Organization And Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Development regulatory and sales milestones payments |  | $ 1,900,000,000 |  |  |  |  |  |  |  |

X
- Definition Cash received as due under collaboration agreement. + References No definition available. + Details
Name: | arwr_CashReceivedAsDueUnderCollaborationAgreement
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development regulatory and sales milestones payments. + References No definition available. + Details
Name: | arwr_DevelopmentRegulatoryAndSalesMilestonesPayments
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Increase decrease in cash and investments. + References No definition available. + Details
Name: | arwr_IncreaseDecreaseInCashAndInvestments
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment earned. + References No definition available. + Details
Name: | arwr_MilestonePaymentEarned
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone payment received. + References No definition available. + Details
Name: | arwr_MilestonePaymentReceived
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of additional targets for development and sales milestone payments. + References No definition available. + Details
Name: | arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments
Namespace Prefix: | arwr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option payments, and development, regulatory and sales milestone payments. + References No definition available. + Details
Name: | arwr_OptionPaymentsAndDevelopmentRegulatoryAndSalesMilestonesPayment
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Organization and significant accounting policies. + References No definition available. + Details
Name: | arwr_OrganizationAndSignificantAccountingPoliciesLineItems
Namespace Prefix: | arwr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_CashAndCashEquivalentsAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation. + References No definition available. + Details
Name: | us-gaap_CashFDICInsuredAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562 + Details
Name: | us-gaap_HeldToMaturitySecuritiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562 + Details
Name: | us-gaap_HeldToMaturitySecuritiesNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 28A -URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585 + Details
Name: | us-gaap_RestrictedCashAndCashEquivalents
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arwr_AmgenIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_AMG890AROLPAAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |